Lexicon Pharmaceuticals is a biopharmaceutical company that develops and commercializes small-molecule medicines targeting cardiovascular disease, metabolic disorders, and neuropathic pain conditions. The company's core product is INPEFA, an FDA-approved dual SGLT1/SGLT2 inhibitor for heart failure that is sold in the United States through a direct sales force and pharmaceutical wholesalers. Lexicon generates revenue through two primary channels: direct commercialization of INPEFA and partnerships with major pharmaceutical companies (including Novo Nordisk, Viatris, and Bristol-Myers Squibb) that provide upfront payments, milestone achievements, and tiered royalties on drug sales. The company employs a proprietary gene knockout discovery platform to identify potential drug targets from thousands of genes, enabling systematic development of candidates across cardiovascular, metabolic, and neurological indications, while outsourcing all manufacturing to contract organizations.